IL11 and steatosis: Previous studies have also proven that the activation (phosphorylation) of ERK and the expression of fibrosis markers are inhibited by inhibiting IL-11, which reduces hepatocyte death and liver fibrosis, inflammation, and steatosis in non-alcoholic steatohepatitis models [49].